SunTrust Robinson Humphrey Downgrades Merck (MRK) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Jefferies Upgrades Merck (MRK) to Hold
October 31, 2017 3:51 AM EDTJefferies upgraded Merck (NYSE: MRK) from Underperform to Hold with a price target of $55.00 (from $54.00).
Analyst Jeffery Holford believes the sharp move lower recently has removed much of the downside he previously suspected would manifest and now moves to the... More
Merck (MRK) PT Lowered to $67 at UBS on 'Keynote-189 Delay As Feared'
October 30, 2017 10:45 AM EDTUBS lowered its price target on Merck (NYSE: MRK) to $67.00 (from $72.00) while maintaining a Buy rating, following the announcement that management would push out results into early 2019 for Keynote-189 in lung cancer.
Analyst Marc Goodman notes a cautious outlook on the shares as... More
Merck (MRK) PT Lowered to $64 at Bernstein
October 30, 2017 8:09 AM EDTBernstein lowered its price target on Merck (NYSE: MRK) to $64.00 (from $65.00) while maintaining a Outperform rating.
Analyst Tim Anderson defends the name noting he continues to view the IO landscape as a "fluid one" and notes risks to IO forecasts are... More
Merck (MRK) PT Lowered to $69 at Leerink Partners
October 30, 2017 7:49 AM EDTLeerink Partners lowered its price target on Merck (NYSE: MRK) to $69.00 (from $70.00) while maintaining a Market Perform rating following results
Analyst Seamus Fernandez said the majority of the bottom-line beat came from other income and a lower-than-anticipated tax rate.
... MoreMorgan Stanley Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:11 AM EDTMorgan Stanley downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $56.00 (from $69.00).
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $58.24 Friday.
... MoreBarclays Downgrades Merck (MRK) to Equalweight
October 30, 2017 2:05 AM EDTBarclays downgraded Merck (NYSE: MRK) from Overweight to Equalweight with a price target of $62.00 (from $72.00).
Analyst Geoff Meacham cites limited upside potential for the equity originating from Keytruda which is "by far Meerck's biggest value driver." The analyst notes headwinds to the... More
Merck (MRK) Withdraws European Application for KEYTRUDA in Combination with Pemetrexed and Carboplatin for First-Line Treatment of NSCLC
October 27, 2017 4:18 PM EDTMerck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has withdrawn its European application for KEYTRUDA® (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC).
... More
